Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.68 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | STAT3 | P40763 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.49 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704436 | 0.86 | SMN1; SMN2 (0.65) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 | |
| SCHEMBL561255 | 0.76 | SMN1; SMN2 (0.58) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 | |
| SCHEMBL757524 | 0.76 | PTGER1 (0.67) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 | |
| SCHEMBL759700 | 0.76 | PTGER1 (0.78) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 | |
| SCHEMBL755782 | 0.76 | PTGER1 (0.63) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 | |
| SCHEMBL4496456 | 0.76 | SMN1; SMN2 (0.72) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 | |
| SCHEMBL694365 | 0.76 | ALDH1A1 (0.56) | PTGER1LMNAALDH1A1MAPTHPGD | |
| SCHEMBL24335934 | 0.75 | SMN1; SMN2 (0.79) | PTGER1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL757179 | 0.74 | PTGER1 (0.75) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 | |
| SCHEMBL757815 | 0.73 | STIM1 (0.56) | PTGER1SMN1; SMN2LMNAALDH1A1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | claimed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-04-20 | — | — | US | disclosed |
| EP-4121089-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | Calcimedica, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021189013-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | CALCIMEDICA, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | MAVS, ATF1, IL1B | PTGER1 552/4885SMN1; SMN2 4507/4885LMNA 928/4885 |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, EIF2AK2 | PTGER1 3463/4885SMN1; SMN2 498/4885LMNA 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.